En

Executive Committee (EC)

The EC consists of seven members: the President, the President Elect or the Past President, the Secretary, the Treasurer, and three additional members. All members of the EC, except the President and the Past President, are elected by secret ballot by the Council during a meeting of the Council. After a term of one year, the President Elect will automatically become President.

The members of the EC are not delegates of their respective countries. All details about the election process can be found in the statutes of the EFMC.

Previous composition of the EC can be found here

Novartis, Switzerland
AUBERSON

Yves P. Auberson obtained his Ph.D. in 1990 at the Swiss Federal Institute of Technology in Lausanne, Switzerland. He joined the Novartis Institute for BioMedical Research in Basel, Switzerland in 1992, after a post-doctoral training in chemical biology at Affymax in Palo Alto, USA.

He is currently Executive Director in Global Discovery Chemistry, where his research group develops tracers for clinical imaging. Previously, he was Head of Chemistry for Neuroscience, and played a leading role in the discovery and development of drug candidates for the treatment of epilepsy, Alzheimer’s disease and narcolepsy.

He is President of the European Federation of Medicinal Chemistry (EFMC), and of the Division of Medicinal Chemistry and Chemical Biology of the Swiss Chemical Society.

University of Lisbon, Portugal
MOREIRA

Rui Moreira completed his Master degree at the Faculty of Pharmacy, University of Lisbon, and obtained his PhD under supervision of Professors Eduarda Rosa (University of Lisbon) and Jim Iley (The Open University). After a postdoctoral stay in the UK, Rui started his career as an independent scientist in Lisbon in 1993 and was promoted to Professor of Medicinal Chemistry in 2006, becoming Head of Department in 2010-2016, and Director of the Research Institute for Medicines (iMed.ULisboa) in 2010-2013.

Rui has wide research interests in the fields of Medicinal and Physical Organic Chemistry, covering the development of anti-infectious and anticancer agents, prodrug chemistry, structure-reactivity-metabolism relationships, design of covalent inhibitors, and design of chemical probes for activity- and photoaffinity-based protein profiling. He has published over 140 papers (Researcher ID G-7485-2011 and ORCID ID 0000-0003-0727-9852) and supervised/co-supervised more than 20 PhD students.

Rui was co-founder of the Medicinal Chemistry Division of the Portuguese Chemical Society, and as served EFMC as Council member in 2008-2015 and as Executive Committee member since 2015. He will be the EFMC President Elect starting in January 2020. 

Uppsala University, Sweden
KARLÉN

Anders Karlén specializes in the field of computational medicinal chemistry and focuses on hit identification and lead development in drug discovery. His group works closely with synthetic medicinal chemists on targets of importance in infectious diseases with a focus on Tuberculosis, Malaria and gram-negative infections. Several of these projects have been run within EU framework 6 and 7 programmes.

He is presently the overall medicinal chemistry project leader for drug discovery efforts currently directed at five different anti-bacterial targets. Since February 2014 he is the Leader of the Managing Entity and co-coordinator of the €85 million, 6 year, Innovative Medicines Initiative (IMI) project ENABLE (European Gram Negative Antibacterial Engine).

 

Esteve Pharmaceuticals, Spain
TORRENS

Antoni Torrens studied Pharmaceutical Sciences at theUniversityofBarcelona, and got his PhD in Organic Chemistry in 1990, working in total synthesis of indole alkaloids under the supervision of Professor Joan Bosch. Then he joined Laboratorios Esteve as a medicinal chemist in theResearchCenterfor Drug Discovery.

After working as Project Leader for several years, in 2002 he was promoted to Head of Discovery Chemistry, and in 2006 he was appointed to Director of R&D Chemistry. Currently he is Responsible of External Collaborations and Strategic Alliances at Esteve Pharmaceuticals.

During his career, he has directly contributed to the progress of several research projects in different therapeutic areas, which led to 6 new chemical entities that reached clinical development. Two of them are nowadays in Phase II and Phase III clinical trials.

He is an active participant teacher in Master and Doctorate Courses at several universities in Spain and Portugal and in several European Medicinal Chemistry Summer Schools.

He is member of the Spanish Society of Medicinal Chemistry (SEQT). After six years serving as a member of the Board, from 2011 to 2015 he was elected as President of the SEQT. In 2016 he was also elected as a member of the Executive Committee of the European Federation for Medicinal Chemistry (EFMC). From January 2019 he is serving as EFMC Treasurer.

Consultant, United Kingdom
TOZER

Matt Tozer is an independent medicinal chemistry consultant, who works with clients across the research & development and service sectors.  Notable recent collaborations have included: the University of Sheffield on a substantial small-molecule oncology programme; Cyclofluidic on its AI-driven, integrated discovery services; and Ubiquigent on its DUB-inhibitor platform. 

Matt has a wealth of experience of leadership and management in the biotech and contract research sectors.  As Director of Peakdale Chemistry Services, he was Head of Site for Peakdale’s pioneering embedded unit at Pfzir, UK. 

In parallel, he was Peakdale’s Director of Medicinal Chemistry Services.  He was Director of Medicinal Chemistry UK for the Anglo-Swedish biotech Medivir and is proud to have earned his spurs as a medicinal chemist under the aegis of Sir James Black at the James Black Foundation. 

Matt is an active and dedicated contributor to the Royal Society of Chemistry, notably through the Biological and Medicinal Chemistry Sector and the Organic Division

SCT & Mercachem-Syncom, The Netherlands
VAN HIJFTE

Dr Van Hijfte holds a PhD degree in Chemistry from Gent University (1984, Belgium) with Prof M Vandewalle, and finalized his academic training by a two-year post-doctoral stay at UCSB with Prof RD Little. He started his industrial career as a medicinal chemist at Merrell Dow in 1986 in Strasbourg, France, where he progressed to head of the medicinal chemistry by the time the site had become part of Sanofi in 1998. In 2002 he moved to Janssen, J&J, first as Research Director of their R&D site in Val de Reuil, France, before taking on the role of Senior Director, Head of Medicinal Chemistry EU, at Janssen Research & Development, with responsibility for European-based medicinal chemistry, analytical technologies, and ADMET.

During this tenure, Luc was privileged to contribute to several successful projects, with numerous programs entering into clinical development in the areas of neurosciences, oncology, and infectious diseases. In 2012 Dr Van Hijfte became CSO of NovAliX, Illkirch, France, before moving in 2017 to his actual position of Sr VP Medicinal Chemistry at Mercachem-Syncom, where he oversees a team of approx. 80 chemists executing medicinal chemistry activities for clients worldwide.

Dr Van Hijfte has been the Vice-President of the French Medicinal Chemistry Society (SCT) in 2015-16, President of the SCT 2017-18, and is currently member of the Executive Committee of the EFMC. In 2018, he has been elected and named member of the “Académie Nationale de Pharmacie” in France, for his multiple contributions to pharmaceutical developments.

Bayer AG, Germany
VON NUSSBAUM